What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

about

What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

Item

http://www.wikidata.org/entity/Q49394586

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

What do we need to make geneti ...... enal cell carcinoma a reality?

@en

What do we need to make geneti ...... enal cell carcinoma a reality?

@nl

type

Item

label

What do we need to make geneti ...... enal cell carcinoma a reality?

@en

What do we need to make geneti ...... enal cell carcinoma a reality?

@nl

prefLabel

What do we need to make geneti ...... enal cell carcinoma a reality?

@en

What do we need to make geneti ...... enal cell carcinoma a reality?

@nl

P1476

What do we need to make geneti ...... enal cell carcinoma a reality?

@en

P2093

Xiaoyan Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Translating pharmacogenomics: challenges on the road to the clinic

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Pharmacogenetics: from bench to byte--an update of guidelines.

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.

P304

1-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/PGS-2016-0168

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meta H Diekstra

Henk-Jan Guchelaar

Jesse J Swen

P577

2016-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27967336

http://www.w3.org/2001/XMLSchema#string

P932

5220441

http://www.w3.org/2001/XMLSchema#string